
Mali ALMA Quarterly Report Quarter Four, 2022




Scorecard for Accountability and Action



Commodities Financed		
LLIN financing 2022 projection (% of need)		100
Public sector RDT financing 2022 projection (% of need)		100
Public sector ACT financing 2022 projection (% of need)		100
Policy		A.
Signed, ratified and deposited the AMA instrument at the AUC		
Malaria activities targeting refugees in Malaria Strategic Plan		
Malaria activities targeting IDPs in Malaria Strategic Plan		
Country Reporting Launch of Zero Malaria Starts with Me Campaign		
Resistance Monitoring, Implementation and Impact	20	
Drug Resistance Monitoring Conducted (2018-2020) and data reported to WHO		
Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010		4
Insecticide resistance monitored since 2015 and data reported to WHO		
National Insecticide Resistance Monitoring and Management Plan		
RDTs in stock (>6 months stock)		
ACTs in stock (>6 months stock)		
LLIN/IRS campaign on track		
Operational LLIN/IRS coverage (% of at risk population)		100
On track to reduce case incidence by ≥40% by 2021 (vs 2015)		
On track to reduce case mortality by ≥40% by 2021 (vs 2015)		
Tracer Indicators for Maternal and Child Health, NTDs an	d C	ovid 19
Scale of Implementation of iCCM		
Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021)	•	25
Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021)		42
Vitamin A Coverage 2021 (2 doses)	•	85
DPT3 coverage 2021 (vaccination among 0-11 month olds)		77
N 25		11

Malaria transmission is more intense in the south of Mali. The annual reported number of malaria cases in 2021 was 3,561,370 with 1,480 deaths.

Key



Mali ALMA Quarterly Report Quarter Four, 2022



Malaria

Global Fund Update

The Global Fund has announced that Mali will receive US\$179.6 million for HIV, tuberculosis, malaria, and health systems strengthening as the country allocation for 2024-2026. The Global Fund has determined the total allocation amount based on Mali's disease burden and income level, as well as several other factors. The malaria component is also allocated a specific proportion of the total, according to a formula developed by the Global Fund that takes into account several factors, including disease burden and the importance of sustaining life-saving essential services. For Mali this is calculated at US\$99.2 million. The allocations to the individual disease components are not fixed, and can be adjusted according to decisions made at country level. Mali is urged to ensure that resources are allocated to malaria control from the overall Global Fund country allocation, as well as from domestic resources, to accelerate progress.

Progress

The country continues to work on strengthening and maintaining health services following the devastating impact of the COVID-19 pandemic. In this regard, Mali has procured sufficient LLINs to achieve universal operational coverage of the targeted atrisk population. The country has carried out insecticide resistance monitoring since 2015 and has reported the results to WHO. There are sufficient resources to procure the ACTs, RDTs and ITNs needed in 2022 and have good levels of stocks. The country has carried out insecticide resistance monitoring since 2015 and has reported the results to WHO and has carried out drug resistance testing since 2018 and has reported the results to WHO. The country is also showing leadership in malaria control through its participation in the High Burden High Impact Approach. The country has also launched the Zero Malaria Starts with Me campaign.

In line with the priority agenda of the ALMA chair, His Excellency President Umaro Sissoco Embaló, Mali has significantly enhanced the tracking and accountability mechanisms for malaria with the development of the Malaria Control Scorecard, although this scorecard is not yet posted to the ALMA Scorecard Hub.

Impact

The annual reported number of malaria cases in 2021 was 3,561,370 with 1,480 deaths.

Key Challenge

 Sustaining the delivery of essential life-saving interventions during the COVID-19 pandemic including for Reproductive, Maternal, Newborn, Adolescent and Child health, malaria and Neglected Tropical Diseases. **Previous Key Recommended Action**

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
Impact	Ensure that malaria services including case management and vector control are sustained and implemented whilst using COVID-19 sensitive	Q4 2022		The NMCP conducted the external review of the MPR in Q4 2022. The ITN campaign planning meetings for the 2023 mass campaign distribution are ongoing. The 4th round of the SMC was implemented. The NMCP conducted supervision in 4 regions and the training of data managers in the use of the OTSS. ITNs were distributed to children U1 and PW at health facility level

RMNCAH and NTDs

Progress

Mali have achieved high coverage of the RMNCAH tracer indicator, vitamin A, The country has significantly enhanced the tracking and accountability mechanisms with the development of a Reproductive, Maternal, Newborn, Child and Adolescent Health Scorecard and has published it on the ALMA Scorecard Hub.

Progress in addressing Neglected Tropical Diseases (NTDs) in Mali is measured using a composite index calculated from preventive chemotherapy coverage achieved for lymphatic filariasis, onchocerciasis, schistosomiasis and trachoma. In 2021, preventive chemotherapy coverage was 100% for lymphatic filariasis, for soil transmitted helminthiasis and for trachoma; 95% for schistosomiasis and 0% for onchocerciasis. Overall, the NTD preventive chemotherapy coverage index for Mali in 2021 is 25, which represents a very substantial decrease compared with the 2020 index value of 95.

Previous Key Recommended Actions

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
RMNCAH¹: Impact	Ensure that essential RMNCAH services are sustained and implemented whilst using Covid-19 sensitive guidelines during the pandemic. Address any stock-outs of essential RMNCAH commodities	Q4 2022		The country reports that RMNCAH services are readily available across the country. There has been no break in supply chains in the past 3 months. They also report no break in the provision of services or medicines

¹ RMNCAH metrics, recommended actions and response tracked through WHO

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
NTDs	Ensure that NTD interventions including MDAs, vector control and Morbidity Management and Disability Prevention are sustained and implemented whilst using Covid-19 sensitive guidelines during the pandemic. This includes prioritising key necessary catch-up activities	Q4 2022		The country is conducting NTD control and preventive measures by respecting COVID-19 measures. In Q4 2022, Transmission Assessment 3 (TAS3) and Morbidity Management and Disability Prevention for Lymphatic Filariasis were conducted. The country is working on the elimination dossiers of Human African Trypanosomiasis, Trachoma, Guinea worm and Lymphatic Filariasis. The country also adopted a new strategy of active participation of the communities in the MDAs by engaging them in the distribution of MDA drugs. MDA for onchocerciasis is being conducted, to be completed by December 2022.
Optimise quality of care	Address the falling coverage of vitamin A	Q4 2022		The country significantly increased the coverage of vitamin A in 2021 to 85%

The country has responded positively to the RMNCAH recommended action addressing the low coverage of ARTs, with small increases in coverage reported.

New Key Recommended Action

Objective	Action Item	Suggested completion timeframe
NTDs	Ensure that NTD interventions including Mass Drug Administration, particularly for soil transmitted helminths, are implemented	Q4 2023

